Credit Suisse Believes Sanofi (SNYNF) Still Has Room to Grow


In a report released today, Trung Huynh from Credit Suisse maintained a Buy rating on Sanofi (SNYNF), with a price target of EUR96.00. The company’s shares closed last Thursday at $105.99, close to its 52-week high of $108.61.

According to TipRanks.com, Huynh is a 4-star analyst with an average return of 10.8% and a 84.2% success rate. Huynh covers the Healthcare sector, focusing on stocks such as Roche Holding AG, AstraZeneca, and Grifols SA.

Sanofi has an analyst consensus of Moderate Buy, with a price target consensus of $117.44, implying a 10.8% upside from current levels. In a report issued on April 14, J.P. Morgan also maintained a Buy rating on the stock with a EUR93.00 price target.

See today’s analyst top recommended stocks >>

Based on Sanofi’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $9.74 billion and net profit of $1.08 billion. In comparison, last year the company earned revenue of $9.92 billion and had a net profit of $1.77 billion.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Human Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes & cardiovascular, established prescription products and generics, together with research, development and production activities. This segment also includes all associates whose activities are related to pharmaceuticals. The Consumer Healthcare segment comprises, for all geographical territories, the commercial operations for its Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines. The company was founded in 1973 and is headquartered in Paris, France.

Read More on SNYNF:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts